Navigation Links
The International Myeloma Foundation Says New Clinical Trial,Results Could Improve Survival While Reducing Side Effects For Many,Patients

- Findings Show Survival Improvement with Lower Doses of Dexamethasone, the Steroid Commonly Used with REVLIMID and other Drugs in Newly Diagnosed Myeloma -

NORTH HOLLYWOOD, Calif., April 04, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said physicians should consider lowering the dose of the steroid dexamethasone when treating patients with multiple myeloma. High dose dexamethasone has been used as standard therapy for the treatment of myeloma alone and in combination with other drugs. However, interim findings from a large ongoing clinical trial of REVLIMID(R) plus dexamethasone in newly diagnosed patients, suggest lowering the "dex" dose may not only reduce side effects, but also may improve survival.

The trial, known as E4A03, is sponsored by the National Cancer Institute and led by the Eastern Cooperative Oncology Group (ECOG). Based on these findings, ECOG has suspended further patient enrollment for this trial and has recommended that lower dose "dex" be considered for patients currently being treated on the high dose arm of the trial. Because of the public health implications, these findings are being made public immediately. The complete details will be presented at a cancer conference later this spring.

"Improved survival with low dose 'dex' and REVLIMID is an important finding because it further improves the outcome for an already successful treatment, while low dose dexamethasone is better tolerated by patients," said Brian G. M. Durie, M.D., chairman and co-founder of the International Myeloma Foundation. "We are recommending that physicians consider these findings when treating their patients across all stages of myeloma and that patients discuss these findings with their physicians."

Susie Novis, president and co-founder of
'"/>




Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... company specializing in oncology, today announced that David ... at BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on ... Time. The conference will take place at the Millennium ... . A live and archived webcast of ...
(Date:9/18/2014)... 18, 2014  Low T Center endorses the ... Hyattsville, Maryland earlier this ... proper patient population for testosterone therapy (TRT), as ... with TRT. Examining recent claims from studies that TRT ... epidemiological studies do not provide convincing evidence that ...
(Date:9/18/2014)... , Sept. 18, 2014   MacPractice,s MacPractice ... Edition Complete EHR certification, which designates that the software ... Stage 1 and Stage 2 Meaningful Use measures required ... Reinvestment Act (ARRA).  MacPractice MD MU version 5.0 was ... , an Office of the National Coordinator-Authorized Certification Body ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3Low T Center Endorses The Joint FDA Committee Meeting on Testosterone 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 2MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 3MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 4MacPractice MD MU Achieves ONC HIT 2014 Edition Complete EHR Certification from ICSA Labs 5
... 2011 Heska Corporation (NASDAQ: ... veterinary diagnostic and other specialty veterinary products , today ... best practices research, tools and metrics for patent analysis ... Heska,s Science Strength in the top 50 of the ...
... released by SCM: (Photo:   http://photos.prnewswire.com/prnh/20111006/LA81891 ) ... of closing statements, lead trial attorney for the plaintiffs in ... asked jurors to bring a verdict of $10 million in ... for James Arnold and to consider whether the Arnolds should ...
Cached Medicine Technology:The Patent Board, IP Tracking and Analysis Firm, Ranks Heska's Science Strength in Biotechnology Industry Top 50 2Lead Trial Attorney in Clark County Hepatitis C Trial, Robert Eglet, Asks Jury to Award $10 Million Compensatory Damages for Anne Arnold, $2.5 Million for James Arnold 2
(Date:9/19/2014)... 2014 United Benefit Advisors (UBA), ... its annual Fall Meeting & Expo at the ... Illinois. With a fantastic attendance of more ... new CEO, Les McPhearson, led these thought leaders ... what is required of successful advisor firms looking ...
(Date:9/19/2014)... September 19, 2014 Script Relief, ... on all commonly prescribed high blood pressure medications. ... drug coupons and has saved its users over ... of making prescription medications more accessible and affordable, ... blood pressure medications. , High blood pressure, also ...
(Date:9/19/2014)... Indiana Fiber Network, LLC (IFN), the leading Indiana ... Fiber Transport Services, adding Point of Presence (PoP) at ... PoP at Cermak, IFN enables interconnect opportunities for Carriers, ... fiber transport service to US and Global Carriers. ... Sales and Marketing August Zehner, establishing a PoP at ...
(Date:9/19/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Potassium Chloride . , The FDA announced on ... lot of Potassium Chloride Injection 10mEq per 100mL due to ... intravenously, is used to treat potassium deficiency. , The ... on the shipping cartons in a single lot where, for ...
(Date:9/19/2014)... A McLean County woman filed ... following a failed hip replacement using a DePuy XL ... Inc. and Johnson & Johnson over allegations that they ... nationally known personal injury law firm, represents defective hip ... involving defective hips. , According to the lawsuit, Owens ...
Breaking Medicine News(10 mins):Health News:United Benefit Advisors New CEO Presides Over Fall Meeting & Expo 2Health News:United Benefit Advisors New CEO Presides Over Fall Meeting & Expo 3Health News:HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications 2Health News:HelpRx.info Now Providing Discounts on All Common High Blood Pressure Medications 3Health News:Indiana Fiber Network Launches Point-Of-Presence in Chicago Data Center at Cermak 2Health News:Baxter Recalls Potassium Chloride Injection: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Flood Law Group Comments on Recent Hip Replacement Lawsuit 2
... Feb. 2 Healthcare Realty Trust Incorporated (NYSE: ... the quarter ended December 31, 2009 .  This dividend, in ... March 4, 2010 to shareholders of record on ... real estate investment trust that integrates owning, managing and developing income-producing ...
... diagnosed with prostate cancer may increase a man,s risk ... according to a new study published online February 2 ... . To study the risks men diagnosed with ... M.D., of the Channing Laboratory, Department of Medicine, Brigham ...
... were shocked to discover that virtually all human embryonic stem ... used to line Petri dishes had left traces on the ... human body they likely would have been rejected by the ... lines approved for use in medical research, there remains a ...
... ... accreditation to the Oakland University William Beaumont School of Medicine. , ... (Vocus) February 2, 2010 -- The Liaison ... Beaumont School of Medicine ., , , , ,The LCME is the national accrediting authority ...
... found , TUESDAY, Feb. 2 (HealthDay News) -- High ... are at risk for kidney failure and associated problems, a ... the Feb. 3 issue of the Journal of the ... protein levels in urine (proteinuria) be incorporated into upcoming new ...
... babies, ability to respond to low oxygen, study suggests, , ... brain chemical serotonin may be crucial to sudden infant death ... SIDS had significantly lower levels of serotonin -- an important ... -- compared to babies who died of other causes, the ...
Cached Medicine News:Health News:Healthcare Realty Trust Announces Fourth Quarter Dividend 2Health News:Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis 2Health News:3-D scaffold provides clean, biodegradable structure for stem cell growth 2Health News:3-D scaffold provides clean, biodegradable structure for stem cell growth 3Health News:Oakland University William Beaumont School of Medicine Reaches Development Milestone 2Health News:Protein Levels in Urine Help Predict Kidney Function 2Health News:Protein Levels in Urine Help Predict Kidney Function 3Health News:Serotonin May Be Key to Sudden Infant Deaths 2Health News:Serotonin May Be Key to Sudden Infant Deaths 3
Upon application to intact skin, Skin-Prep* protective wipes forms a protective film that prepares the skin for the attachment of drainage tubes, external catheters, adhesive dressings and can be...
Triad Plus Sterile Isopropyl Alcohol 70% USP Prep Pads are medium size. Each package is terminally sterilized, ensuring the safest possible product....
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th...
... Triad Plus Sterile ... Swabsticks are primarily used ... prior to administering injections. ... to meet AAMI/ANSI/ISO 11137 ...
Medicine Products: